Jones Financial Companies Lllp Has $916,000 Stock Position in Guardant Health, Inc. $GH

Jones Financial Companies Lllp boosted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 87.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,251 shares of the company’s stock after purchasing an additional 7,119 shares during the period. Jones Financial Companies Lllp’s holdings in Guardant Health were worth $916,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Sound Income Strategies LLC acquired a new stake in Guardant Health in the third quarter valued at about $38,000. IFP Advisors Inc boosted its stake in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Guardant Health by 358.4% during the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock valued at $37,000 after purchasing an additional 552 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Guardant Health during the 2nd quarter worth approximately $62,000. Finally, Bayforest Capital Ltd acquired a new position in Guardant Health during the 3rd quarter worth approximately $78,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Guardant Health from $100.00 to $125.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. Piper Sandler increased their target price on Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Barclays boosted their price target on Guardant Health from $85.00 to $120.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $106.86.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 31,452 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a total transaction of $3,241,757.64. Following the sale, the insider owned 25,987 shares of the company’s stock, valued at approximately $2,678,480.09. This represents a 54.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total value of $10,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 168,223 shares of the company’s stock, valued at approximately $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 434,627 shares of company stock valued at $45,592,052 over the last three months. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Price Performance

Guardant Health stock opened at $107.58 on Thursday. The stock’s 50 day moving average is $106.44 and its 200 day moving average is $83.20. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74. The firm has a market cap of $13.56 billion, a P/E ratio of -33.51 and a beta of 1.63.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.